GC Medical Science, Yuwell Target CGM Market
GC Medical Science is joining hands with Yuwell, a powerhouse in the Chinese medical device market, to target the continuous glucose monitoring (CGM) market. GC Medical Science announced on Oct. 14 that it signed a memorandum of understanding (MOU) to establish a strategic partnership at Yuwell's he
GC Medical Science and Yuwell, a leading Chinese medical device company, have announced a strategic partnership to enter the continuous glucose monitoring (CGM) market. This collaboration was formalized with a memorandum of understanding (MOU) signed on October 12 at Yuwell's headquarters in China, building upon the existing partnership facilitated by the GCFiT home medical device brand.
The primary goal of this joint venture is to introduce Yuwell's CGM products to the domestic market. CGM devices provide real-time monitoring of blood glucose levels via sensors attached to the skin, playing a crucial role in diabetes management. GC Medical Science will handle domestic approvals, regulatory compliance, marketing, sales, and distribution, while Yuwell will manage technical documentation, clinical data, manufacturing quality assurance, and production.
Both companies aim to leverage their respective strengths - GC Medical Science's domestic sales network and Yuwell's manufacturing capabilities - to maximize synergy. Specific business details such as pricing, sales volume, and exclusive distribution rights are expected to be determined through further discussions. Established in 1998 and listed on the Shenzhen Stock Exchange, Yuwell has become a notable player in China's medical device industry.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
